{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,28]],"date-time":"2026-04-28T22:46:49Z","timestamp":1777416409109,"version":"3.51.4"},"reference-count":56,"publisher":"MDPI AG","issue":"2","license":[{"start":{"date-parts":[[2026,1,26]],"date-time":"2026-01-26T00:00:00Z","timestamp":1769385600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Medicina"],"abstract":"<jats:p>Background and Objectives: Biological therapies improve disease severity and quality of life in patients with psoriasis, but data on Romanian patients remain limited. Our study aimed to characterize patients with psoriasis from Transylvania and to evaluate the impact of biologics on disease severity, treatment switching, affected special areas response, quality of life, and laboratory biomarkers. Materials and Methods: We conducted a retrospective exploratory study at two centers in Cluj-Napoca, Romania, using routinely collected medical data. Results: One-hundred and fifteen patients (aged 2\u201372 years) were evaluated; 45 patients received anti-TNF, 43 received anti-IL-17, and 27 received anti-IL-23. Patients treated with anti-IL-17 or anti-IL-23 were older at diagnosis than those treated with anti-TNF (p = 0.0001). Psoriatic lesions were prevalent in the scalp (58.3%) and nails (36.5%). Methotrexate was the most common prior systemic therapy (87.8%), with no difference between the groups (p = 0.7668). Patients receiving anti-TNF therapy (46.7%) or anti-IL-17 therapy (20.9%) also most frequently received prior treatment with systemic retinoids. Cardiometabolic comorbidities, including hypertension (40.9%) and diabetes mellitus (20.9%), were prevalent. Anti-IL-17 therapies were used more frequently in patients with hypertension (46.5%), diabetes mellitus (34.9%), and psoriatic arthritis (34.9%). Baseline severity scores were comparable across the groups (p &gt; 0.10). A therapeutic switch occurred in approximately one-quarter of the patients, most frequently in the anti-TNF group (57.8%), which also showed higher PASI and DLQI scores at switching (p &lt; 0.0001). At 36 weeks, anti-IL-17 and anti-IL-23 therapies demonstrated superior outcomes compared to anti-TNF therapy (p = 0.045). All patients receiving anti-IL-23 therapy achieved a PASI 100 at the 60-week follow-up. Significant improvements in PASI and DLQI were observed for all biologics (p &lt; 0.0001). Conclusions: Biological therapies were associated with significant improvements in disease severity and quality of life. Anti-TNF therapies were switched more frequently due to reduced efficacy, while clinical improvement was observed regardless of lesion localization.<\/jats:p>","DOI":"10.3390\/medicina62020257","type":"journal-article","created":{"date-parts":[[2026,1,26]],"date-time":"2026-01-26T10:24:36Z","timestamp":1769423076000},"page":"257","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Exploratory Retrospective Assessment of Patients with Psoriasis Receiving Biological Therapy"],"prefix":"10.3390","volume":"62","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-8428-8088","authenticated-orcid":false,"given":"Andrada-Luciana","family":"Lazar","sequence":"first","affiliation":[{"name":"4th Medical Clinic, Internal Medicine Department, \u201cIuliu Ha\u0163ieganu\u201d University of Medicine and Pharmacy Cluj-Napoca, 400347 Cluj-Napoca, Cluj, Romania"},{"name":"Dermatology Department Integrated Ambulatory\u2014Infectious Diseases Clinical Hospital Cluj-Napoca, 400001 Cluj-Napoca, Cluj, Romania"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2342-4311","authenticated-orcid":false,"given":"Sorana D.","family":"Bolboac\u0103","sequence":"additional","affiliation":[{"name":"Medical Informatics and Biostatistics, Department 11\u2014Medical Education, Faculty of Medicine, \u201cIuliu Ha\u021bieganu\u201d University of Medicine and Pharmacy Cluj-Napoca, 400349 Cluj-Napoca, Cluj, Romania"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Adrian-Lucian","family":"Baican","sequence":"additional","affiliation":[{"name":"Department of Dermatology, \u201cIuliu Ha\u021bieganu\u201d University of Medicine and Pharmacy Cluj-Napoca, 400347 Cluj-Napoca, Cluj, Romania"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Corina-Iulia","family":"Baican","sequence":"additional","affiliation":[{"name":"Department of Dermatology, County Emergency Hospital, 400535 Cluj-Napoca, Cluj, Romania"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0968-4026","authenticated-orcid":false,"given":"Sorina","family":"D\u0103nescu","sequence":"additional","affiliation":[{"name":"Department of Dermatology, \u201cIuliu Ha\u021bieganu\u201d University of Medicine and Pharmacy Cluj-Napoca, 400347 Cluj-Napoca, Cluj, Romania"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Elisabeta","family":"Candrea","sequence":"additional","affiliation":[{"name":"Department of Dermatology, \u201cIuliu Ha\u021bieganu\u201d University of Medicine and Pharmacy Cluj-Napoca, 400347 Cluj-Napoca, Cluj, Romania"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5997-8586","authenticated-orcid":false,"given":"Diana Valentina","family":"C\u00e2mpean","sequence":"additional","affiliation":[{"name":"Dermatology Department Integrated Ambulatory\u2014Infectious Diseases Clinical Hospital Cluj-Napoca, 400001 Cluj-Napoca, Cluj, Romania"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5263-2163","authenticated-orcid":false,"given":"Paula","family":"Ilu\u021b","sequence":"additional","affiliation":[{"name":"Dermatology Department Integrated Ambulatory\u2014Infectious Diseases Clinical Hospital Cluj-Napoca, 400001 Cluj-Napoca, Cluj, Romania"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ioana","family":"Semenescu","sequence":"additional","affiliation":[{"name":"Dermatology Department Integrated Ambulatory\u2014Infectious Diseases Clinical Hospital Cluj-Napoca, 400001 Cluj-Napoca, Cluj, Romania"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8590-4583","authenticated-orcid":false,"given":"Adela-Viviana","family":"Sitar-T\u0103ut","sequence":"additional","affiliation":[{"name":"4th Medical Clinic, Internal Medicine Department, \u201cIuliu Ha\u0163ieganu\u201d University of Medicine and Pharmacy Cluj-Napoca, 400347 Cluj-Napoca, Cluj, Romania"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2476-9706","authenticated-orcid":false,"given":"Romana","family":"Vulturar","sequence":"additional","affiliation":[{"name":"Department of Cell and Molecular Biology, \u201cIuliu Ha\u0163ieganu\u201d University of Medicine and Pharmacy Cluj-Napoca, 400349 Cluj-Napoca, Cluj, Romania"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Olga Hilda","family":"Or\u0103\u0219an","sequence":"additional","affiliation":[{"name":"4th Medical Clinic, Internal Medicine Department, \u201cIuliu Ha\u0163ieganu\u201d University of Medicine and Pharmacy Cluj-Napoca, 400347 Cluj-Napoca, Cluj, Romania"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3989-2291","authenticated-orcid":false,"given":"Angela","family":"Cozma","sequence":"additional","affiliation":[{"name":"4th Medical Clinic, Internal Medicine Department, \u201cIuliu Ha\u0163ieganu\u201d University of Medicine and Pharmacy Cluj-Napoca, 400347 Cluj-Napoca, Cluj, Romania"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1968","published-online":{"date-parts":[[2026,1,26]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"983","DOI":"10.1016\/S0140-6736(14)61909-7","article-title":"Psoriasis","volume":"386","author":"Boehncke","year":"2015","journal-title":"Lancet"},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"adv42945","DOI":"10.2340\/actadv.v105.42945","article-title":"Epidemiology of Psoriasis: A Worldwide Global Study","volume":"105","author":"Skayem","year":"2025","journal-title":"Acta Derm. Venereol."},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"m1590","DOI":"10.1136\/bmj.m1590","article-title":"National, regional, and worldwide epidemiology of psoriasis: Systematic analysis and modelling study","volume":"369","author":"Parisi","year":"2020","journal-title":"BMJ"},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"1599","DOI":"10.1111\/ijd.17848","article-title":"Epidemiology of Psoriasis in Poland: Prevalence, Incidence, and Mortality Rates","volume":"64","author":"Szepietowski","year":"2025","journal-title":"Int. J. Dermatol."},{"key":"ref_5","doi-asserted-by":"crossref","unstructured":"Nicolescu, A.C., Bucur, \u0218., Giurc\u0103neanu, C., Gheuc\u0103-Solov\u0103stru, L., Constantin, T., Furtunescu, F., Ancu\u021ba, I., and Constantin, M.M. (2021). Prevalence and Characteristics of Psoriasis in Romania\u2014First Study in Overall Population. J. Pers. Med., 11.","DOI":"10.3390\/jpm11060523"},{"key":"ref_6","first-page":"900","article-title":"The first nation-wide study revealing epidemiologic data and life quality aspects of psoriasis in Romania","volume":"18","author":"Boca","year":"2019","journal-title":"Exp. Ther. Med."},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"377","DOI":"10.1038\/jid.2012.339","article-title":"Global epidemiology of psoriasis: A systematic review of incidence and prevalence","volume":"133","author":"Parisi","year":"2013","journal-title":"J. Investig. Dermatol."},{"key":"ref_8","first-page":"79","article-title":"A brief summary of clinical types of psoriasis","volume":"3","author":"Sarac","year":"2016","journal-title":"North Clin. Istanb."},{"key":"ref_9","doi-asserted-by":"crossref","unstructured":"Bhutani, T., Liao, W., and Nakamura, M. (2018). Psoriasis: Overview and Diagnosis. Evidence-Based Psoriasis, Springer.","DOI":"10.1007\/978-3-319-90107-7"},{"key":"ref_10","first-page":"70","article-title":"Scalp psoriasis","volume":"9","author":"Wozel","year":"2011","journal-title":"J. Dtsch. Dermatol. Ges."},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"206","DOI":"10.1067\/S0190-9622(03)00910-1","article-title":"Nail Psoriasis Severity Index: A useful tool for evaluation of nail psoriasis","volume":"49","author":"Rich","year":"2003","journal-title":"J. Am. Acad. Dermatol."},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1007\/s13555-017-0213-2","article-title":"The Development of a Patient-Reported Outcome Measure for Assessment of Genital Psoriasis Symptoms: The Genital Psoriasis Symptoms Scale (GPSS)","volume":"8","author":"Gottlieb","year":"2018","journal-title":"Dermatol. Ther."},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"419","DOI":"10.5114\/ada.2018.75810","article-title":"Dermatology Life Quality Index and disease coping strategies in psoriasis patients","volume":"36","author":"Liluashvili","year":"2019","journal-title":"Postep. Dermatol. Alergol."},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"2461","DOI":"10.1111\/jdv.16915","article-title":"EuroGuiDerm Guideline on the systemic treatment of Psoriasis vulgaris\u2014Part 1","volume":"34","author":"Nast","year":"2020","journal-title":"J. Eur. Acad. Dermatol. Venereol."},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"122991","DOI":"10.1016\/j.lfs.2024.122991","article-title":"Advances in psoriasis research: From pathogenesis to therapeutics","volume":"355","author":"Sugumaran","year":"2024","journal-title":"Life Sci."},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1038\/s41572-025-00630-5","article-title":"Psoriasis","volume":"11","author":"Armstrong","year":"2025","journal-title":"Nat. Rev. Dis. Primers"},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"2051","DOI":"10.1038\/s41467-025-56719-8","article-title":"GWAS meta-analysis of psoriasis identifies new susceptibility alleles impacting disease mechanisms and therapeutic targets","volume":"16","author":"Dand","year":"2025","journal-title":"Nat. Commun."},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"108","DOI":"10.1186\/s12964-023-01381-0","article-title":"Triggers for the onset and recurrence of psoriasis: A review and update","volume":"22","author":"Liu","year":"2024","journal-title":"Cell Commun. Signal."},{"key":"ref_19","doi-asserted-by":"crossref","unstructured":"Rendon, A., and Sch\u00e4kel, K. (2019). Psoriasis Pathogenesis and Treatment. Int. J. Mol. Sci., 20.","DOI":"10.3390\/ijms20061475"},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"e12946","DOI":"10.1111\/sji.12946","article-title":"The TNF\/IL-23\/IL-17 axis\u2014Head-to-head trials comparing different biologics in psoriasis treatment","volume":"92","author":"Petrovic","year":"2020","journal-title":"Scand. J. Immunol."},{"key":"ref_21","first-page":"39","article-title":"Biologic Treatments of Psoriasis: An Update for the Clinician","volume":"15","author":"Brownstone","year":"2021","journal-title":"Biologics"},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"1131","DOI":"10.1093\/rheumatology\/keae257","article-title":"Treatment of psoriasis with different classes of biologics reduces the likelihood of peripheral and axial psoriatic arthritis development","volume":"64","author":"Floris","year":"2025","journal-title":"Rheumatology"},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"229","DOI":"10.1111\/ijd.17497","article-title":"Psoriasis management tree based on comorbidity","volume":"64","author":"Amara","year":"2025","journal-title":"Int. J. Dermatol."},{"key":"ref_24","first-page":"e63379","article-title":"The Association Between Psoriasis and Atherosclerotic Cardiovascular Disease: A Systematic Review and Meta-Analysis of Observational Studies","volume":"16","author":"Osigwe","year":"2024","journal-title":"Cureus"},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"e2022011","DOI":"10.5826\/dpc.1201a11","article-title":"Prevalence of Atherosclerosis in Psoriatic Patients Detected with Epiaortic Color Doppler Ultrasound and Computed Tomography Angiography","volume":"12","author":"Dattola","year":"2022","journal-title":"Dermatol. Pract. Concept."},{"key":"ref_26","doi-asserted-by":"crossref","unstructured":"Liu, C., Chen, H., Liu, Y., Huang, H., Yu, W., Du, T., Long, X., Chen, X., Chen, Z., and Guo, S. (2022). Immunity: Psoriasis comorbid with atherosclerosis. Front. Immunol., 13.","DOI":"10.3389\/fimmu.2022.1070750"},{"key":"ref_27","doi-asserted-by":"crossref","unstructured":"Su, W., Zhao, Y., Wei, Y., Zhang, X., Ji, J., and Yang, S. (2021). Exploring the Pathogenesis of Psoriasis Complicated with Atherosclerosis via Microarray Data Analysis. Front. Immunol., 12.","DOI":"10.3389\/fimmu.2021.667690"},{"key":"ref_28","first-page":"215","article-title":"Metabolic Syndrome in Psoriasis Patients\u2014An Observational Study","volume":"50","author":"Dinescu","year":"2024","journal-title":"Curr. Health Sci. J."},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"79","DOI":"10.2147\/PTT.S456393","article-title":"Effectiveness and Drug Survival of Ixekizumab and Secukinumab in Patients with Moderate to Severe Plaque Psoriasis","volume":"14","author":"Bucur","year":"2024","journal-title":"Psoriasis"},{"key":"ref_30","doi-asserted-by":"crossref","unstructured":"Mihu, C., Popescu, C.A., Neag, M.A., Boc\u0219an, I.C., Melincovici, C.S., Baican, A.L., N\u0103sui, B.A., and Buzoianu, A.D. (2023). The Psoriasis Disability Index in Romanian Psoriasis Patients during COVID-19 Pandemic. J. Clin. Med., 12.","DOI":"10.3390\/jcm12186000"},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"56","DOI":"10.2478\/jim-2022-0015","article-title":"Psoriasis-Related Stigma: Is There More to Uncover?","volume":"7","author":"Decean","year":"2022","journal-title":"J. Interdiscip. Med."},{"key":"ref_32","first-page":"7","article-title":"Strategies to improve quality of life in psoriasis","volume":"70","author":"Burlacu","year":"2025","journal-title":"DermatoVenerologia"},{"key":"ref_33","unstructured":"(2026, January 18). COD PROTOCOL DENUMIRE [Internet]. [Cited 18 January 2026]. Available online: https:\/\/cnas.ro\/wp-content\/uploads\/2025\/06\/lista-protocoalelor-terapeutice-iunie-2025-site_all.pdf."},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"170","DOI":"10.7861\/clinmed.2021-0257","article-title":"Psoriasis: A brief overview","volume":"21","author":"Raharja","year":"2021","journal-title":"Clin. Med."},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"139","DOI":"10.2147\/PTT.S328572","article-title":"Comorbidity in Adult Psoriasis: Considerations for the Clinician","volume":"12","author":"Daugaard","year":"2022","journal-title":"Psoriasis"},{"key":"ref_36","doi-asserted-by":"crossref","unstructured":"Cai, J., Cui, L., Wang, Y., Li, Y., Zhang, X., and Shi, Y. (2021). Cardiometabolic Comorbidities in Patients with Psoriasis. Front. Pharmacol., 12.","DOI":"10.3389\/fphar.2021.774808"},{"key":"ref_37","first-page":"99","article-title":"Biologics Can Significantly Improve Dermatology Life Quality Index in Psoriatic Patients","volume":"12","author":"Rustemeyer","year":"2022","journal-title":"Psoriasis"},{"key":"ref_38","doi-asserted-by":"crossref","unstructured":"Timis, T.L., Beni, L., Mocan, T., Florian, I.A., and Orasan, R.I. (2023). Biologic Therapies Decrease Disease Severity and Improve Depression and Anxiety Symptoms in Psoriasis Patients. Life, 13.","DOI":"10.3390\/life13051219"},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"11158","DOI":"10.1038\/s41598-025-94505-0","article-title":"BMI matters: Understanding the link between weight and severe psoriasis","volume":"15","author":"Wang","year":"2025","journal-title":"Sci. Rep."},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"1377","DOI":"10.2147\/CCID.S411636","article-title":"A Comparison of Clinical Characteristics in Overweight\/Obese and Normal Weight Patients with Psoriasis Vulgaris","volume":"16","author":"Li","year":"2023","journal-title":"Clin. Cosmet. Investig. Dermatol."},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"S14","DOI":"10.1111\/j.1529-8019.2009.01281.x","article-title":"Correlation between BMI and PASI in patients with moderate to severe psoriasis undergoing biological therapy","volume":"23","author":"Bardazzi","year":"2010","journal-title":"Dermatol. Ther."},{"key":"ref_42","doi-asserted-by":"crossref","unstructured":"Haberman, R.H., Ogdie, A., Merola, J.F., Scher, J.U., and Eder, L. (Nat. Rev. Rheumatol., 2025). The Obesity-Inflammation Axis in Psoriatic Disease: Mechanisms and Therapeutic Strategies, Nat. Rev. Rheumatol., in press.","DOI":"10.1038\/s41584-025-01326-6"},{"key":"ref_43","doi-asserted-by":"crossref","unstructured":"Almenara-Blasco, M., Gracia-Caza\u00f1a, T., Poblador-Plou, B., Laguna-Berna, C., Carmona-P\u00edrez, J., Navarro-Bielsa, A., Prados-Torres, A., Gimeno-Miguel, A., and Gilaberte, Y. (2024). Multimorbidity of Psoriasis: A Large-Scale Population Study of Its Associated Comorbidities. J. Clin. Med., 13.","DOI":"10.3390\/jcm13020492"},{"key":"ref_44","doi-asserted-by":"crossref","first-page":"2","DOI":"10.5070\/D30W66C5GG","article-title":"A systematic review of adverse effects associated with topical treatments for psoriasis","volume":"9","author":"Bruner","year":"2003","journal-title":"Dermatol. Online J."},{"key":"ref_45","doi-asserted-by":"crossref","unstructured":"West, J., Ogston, S., and Foerster, J. (2016). Safety and Efficacy of Methotrexate in Psoriasis: A Meta-Analysis of Published Trials. PLoS ONE, 11, Erratum in: PLoS ONE 2016, 11, e0158928. https:\/\/doi.org\/10.1371\/journal.pone.0158928.","DOI":"10.1371\/journal.pone.0158928"},{"key":"ref_46","doi-asserted-by":"crossref","first-page":"2200870","DOI":"10.1080\/09546634.2023.2200870","article-title":"Real-world switching patterns and associated characteristics in patients with psoriasis treated with biologics in the United States","volume":"34","author":"Armstrong","year":"2023","journal-title":"J. Dermatolog. Treat."},{"key":"ref_47","doi-asserted-by":"crossref","first-page":"2805","DOI":"10.1007\/s13555-024-01258-1","article-title":"Impact of Disease Factors of Patients with Psoriasis and Psoriatic Arthritis on Biologic Therapy Switching","volume":"14","author":"Mease","year":"2024","journal-title":"Dermatol. Ther."},{"key":"ref_48","first-page":"1513","article-title":"Evolution of characteristics and biologic treatment effectiveness in patients of the Austrian psoriasis registry from 2004\u20132022","volume":"21","author":"Graier","year":"2023","journal-title":"J. Dtsch. Dermatol. Ges."},{"key":"ref_49","doi-asserted-by":"crossref","first-page":"15528","DOI":"10.1038\/s41598-025-99075-9","article-title":"Cutaneous and systemic improvements in psoriasis patients after different biologic treatments","volume":"15","author":"Ntawuyamara","year":"2025","journal-title":"Sci. Rep."},{"key":"ref_50","doi-asserted-by":"crossref","first-page":"100","DOI":"10.1177\/24755303231160683","article-title":"Psoriasis Involving Special Areas Is Associated with Worse Quality of Life","volume":"8","author":"Blauvelt","year":"2023","journal-title":"J. Psoriasis Psoriatic Arthritis"},{"key":"ref_51","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1177\/24755303231217491","article-title":"Assessing Comparative Efficacy of Biologics for the Treatment of Psoriasis with Nail Involvement","volume":"9","author":"Khan","year":"2024","journal-title":"J. Psoriasis Psoriatic Arthritis"},{"key":"ref_52","doi-asserted-by":"crossref","first-page":"439","DOI":"10.1159\/000517806","article-title":"Scalp Psoriasis and Biologic Agents: A Review","volume":"7","author":"Papadimitriou","year":"2021","journal-title":"Skin Appendage Disord."},{"key":"ref_53","unstructured":"(2025, November 30). Ordin 1218\/16.09.2010. Portal Legislativ. Available online: https:\/\/legislatie.just.ro\/public\/DetaliiDocument\/123112."},{"key":"ref_54","unstructured":"Eli Lilly (2025, November 30). Rom\u00e2nia Anun\u021b\u0103 Lansarea TALTZ \u00een Tratamentul Psoriazisului Moderat-Sever. MedicalManager 2018. Available online: https:\/\/www.medicalmanager.ro\/eli-lilly-romania-anunta-lansarea-taltz-in-tratamentul-psoriazis-ului-moderat-sever\/."},{"key":"ref_55","unstructured":"(2025, November 30). Anexa 28\/10\/2022. Portal Legislativ. Available online: https:\/\/legislatie.just.ro\/Public\/DetaliiDocumentAfis\/261213."},{"key":"ref_56","unstructured":"Casa Na\u021bional\u0103 de Asigur\u0103ri de S\u0103n\u0103tate (CNAS) (2025, November 30). Protocol List. Available online: https:\/\/cnas.ro\/wp-content\/uploads\/2022\/04\/Binder1-3.pdf."}],"container-title":["Medicina"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/1648-9144\/62\/2\/257\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,1,26]],"date-time":"2026-01-26T10:59:47Z","timestamp":1769425187000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/1648-9144\/62\/2\/257"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,1,26]]},"references-count":56,"journal-issue":{"issue":"2","published-online":{"date-parts":[[2026,2]]}},"alternative-id":["medicina62020257"],"URL":"https:\/\/doi.org\/10.3390\/medicina62020257","relation":{},"ISSN":["1648-9144"],"issn-type":[{"value":"1648-9144","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,1,26]]}}}